Evolving concepts in myelodysplastic syndromes.
Myelodysplastic syndromes continue to be "a riddle, wrapped in a mystery inside of an enigma". Clearly, MDS represent a heterogeneous group of disorders, and no uniform etiology or treatment can be prescribed for all patients. This further underscores the need for MDS patients to be seen at specialized centers and placed on experimental protocols if they need treatment. The important thing to remember is that ultimately, the patient must remain the measure of all things, and must be given all the therapeutic choices including that of waiting and watching with supportive care alone. Recent biologic insights have expanded the therapeutic options, but no curative therapies except stem cell transplants are available at this time. By dissecting the biology and focusing efforts towards understanding the etiology of the cytopenias, significant therapeutic advances are being made in this disease. The momentum built up so far must not be lost now.
Raza
A
A
MDS Center, Section of Myeloid Diseases, Department of Medicine, Rush University, Chicago, IL, USA.
D000368:Aged; D017209:Apoptosis; D001853:Bone Marrow / Q000473:pathology; D001854:Bone Marrow Cells / Q000648:ultrastructure; D002455:Cell Division; D019070:Cell Lineage; D002478:Cells, Cultured / Q000473:pathology; D002869:Chromosome Aberrations; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000502:physiology; D018450:Disease Progression; D005260:Female; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D006965:Hyperplasia; D007239:Infections / Q000150:complications; D007249:Inflammation; D007951:Leukemia, Myeloid / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000628:therapy; D011289:Preleukemia / Q000473:pathology; D017154:Stromal Cells / Q000473:pathology; D014481:United States / Q000453:epidemiology
D016207:Cytokines